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under the CC BY-NC-ND license (http:Summary Objectives: To identify host biomarkers associated with latent tuberculosis infec-
tion (LTBI), active tuberculosis (TB), and nontuberculous mycobacteria (NTM) diseases to
improve diagnosis and effective anti-TB treatment.
Methods: Active TB and NTM patients at diagnosis, recent TB contacts, and normal healthy
subjects were recruited. Tuberculin skin tests, QuantiFERON-TB Gold In-Tube tests, and multi-
plex bead arrays with 17 analytes were performed. TB patients were re-evaluated after 2 and 6
months of treatment.
Results: Mycobacterium tuberculosis (M. tb) antigen-specific IFN-g, IL-2, and CXCL10 re-
sponses were significantly higher in active TB and LTBI compared with controls (P < 0.01). Only
serum VEGF levels varied between the active TB and LTBI groups (AUC Z 0.7576, P < 0.001).
Active TB and NTM diseases were differentiated by serum IL-2, IL-9, IL-13, IL-17, TNF-a and
sCD40L levels (P < 0.05). Increased sCD40L and decreased M. tb antigen-specific IFN-g levels
correlated with sputum clearance of M. tb after 2 months of treatment (P < 0.001).
Conclusions: Serum IL-2, IL-9, IL-13, IL-17, TNF-a, sCD40L and VEGF-A levels may be adjunctive
biomarkers for differential diagnosis of active TB, LTBI, and NTM disease. Assessment of serumof Microbiology and Institute of Immunology and Immunological Diseases, Yonsei University College of
u, Seoul 120-752, South Korea. Tel.: þ82 2 2228 1819; fax: þ82 2 313 7190.
.-N. Cho).
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Biosignatures associated with TB, LTBI, and NTM diseases 347sCD40L and M. tb antigen-specific IFN-g, TNF-a, and IL-2 levels could help predict successful
anti-TB treatment in conjunction with M. tb clearance.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Tuberculosis (TB) remains a major global health problem
with an estimated 8.6 million new cases of TB worldwide in
2012.1 Incidence of TB and its mortality rate have been fall-
ing since 1990, but the global burden remains substantial
due to the slow rate of decline in TB incidence (2% per
year).1 For effective control of TB, rapid and accurate labo-
ratory diagnosis is of utmost importance. Sputum smear mi-
croscopy of acid-fast bacilli (AFB) and culture of M. tb have
been widely used for diagnosis of active TB.2 However, AFB
smear microscopy has limited sensitivity (50e60%) and is
inappropriate for monitoring therapeutic effects, because
it cannot distinguish live from dead bacilli.2 A favourable
outcome of anti-TB treatment is conventionally predicted
by sputum culture conversion within the first two months
of treatment,3 whereas definitive identification of M. tb by
culture takes several weeks.2 The AFB smear test is not spe-
cific to pulmonary TB, because patients with nontuberculous
mycobacteria (NTM) lung disease may show positive results
by the AFB smear test.4 Thus, there is a need for early clin-
ical identification of NTM lung disease among AFB smear-
positive patients as the therapeutic regimens for pulmonary
TB and NTM lung diseases differ. A recently developed mo-
lecular diagnostics such as the Xpert MTB/RIF and line
probe assay contributed to rapid diagnosis of pulmonary
TB and differentiation between M. tb and NTM in AFB
smear-positive specimen.5,6 However, the need of infra-
structure and its high cost compared to smear microscopy
are the major issue for implementation of the technology
in low- and middle-income countries.5
Individuals with latent tuberculosis infection (LTBI) have
a lifetime risk of 10% for progression to active disease. Thus,
control of LTBI with early diagnosis may help effective TB
control accompanied by appropriate treatment of active
cases. A tuberculin skin test (TST) is a traditional method for
detecting LTBI. However, the TST frequently provides false
positive responses in individuals with recent BCG vaccina-
tion or exposure to NTM.7 An IFN-g release assay (IGRA) can
rapidly detect LTBI by measuring in vitro release of IFN-g in
response to M. tb-specific peptide antigens, including early
secreted antigen target, 6 kDa (ESAT-6), culture filtrate pro-
tein 10 kDa (CFP-10), and TB 7.7.8 The IGRA overcomes the
drawbacks of the TST, such as cross-reactivity with antigens
derived fromM. bovis BCG andmost NTM species.6 However,
the IGRA does not discriminate LTBI from active TB upon
diagnosis.9 Discordant performance of IGRA in NTM patients
has been reported; the IGRA holds potential to differentiate
between NTM and M. tb infection in a TB low-incidence
setting10 whereas false positive IGRA in NTM patients was
observed due to high prevalence of LTBI in a population
with a TB high-incidence.11,12 These reports indicate that
IFN-g assessment, by itself, is not sufficient for differential
diagnosis of active TB, LTBI, or NTM diseases, and thereforeputative biomarkers for improving diagnosis and monitoring
therapeutic effects need to be identified for effective TB
control.
In this study, we examined a panel of cytokines in
patients with active TB or NTM diseases, TB contacts, and
normal healthy controls to determine cytokine signatures
according to disease, infection, or treatment state. We
hypothesized that individuals with active TB would have
different cytokine signatures compared with those with
NTM disease or LTBI. In addition, measurement of multiple
cytokines may help identify potential biomarkers not only
for differentiating active TB from LTBI or NTM disease, but
also for predicting host responses during anti-TB treatment.
We aimed to characterize biosignatures as putative bio-
markers, which may be useful at the early phase of
diagnosis and for monitoring therapeutic effects even
before confirmation of M. tb growth or clearance in culture.
Because changes in circulating cytokine or chemokine
levels are associated with human diseases, we performed
multiplex bead arrays measuring 17 analytes including cyto-
kines, chemokines, and a growth factor in serum, as well as
plasma samples that were derived from QuantiFERON-TB
Gold In-Tube (QFT-IT) tests.
Materials and methods
Enrolment of study participants and anti-TB
treatment
From November 2010 to December 2013, 86 TB patients
(mean age of 32 ranged from 20 to 76, 44 males and 42
females) at diagnosis, and 51 individuals who were recently
exposed to TB patients but had no active disease (mean age
of 44 ranged from 18 to 82, 13 males and 38 females) were
enrolled (Fig. 1). A total of 133 normal healthy individuals
(mean age of 31 ranged from 20 to 61, 63 males and 70 fe-
males) recruited had no history of contact with TB patients
and no symptoms of TB with normal observation on chest X-
ray (Fig. 1). Forty-two NTM patients aged 43e84 years at
diagnosis (10 males and 32 females) were also enrolled
and NTM isolates were confirmed from the 42 patients
(Fig. 1). Active pulmonary TB at diagnosis was confirmed
by smear/culture of M. tb from sputa or radiological exam-
ination. Individuals who had immunosuppressants, or any
form of cancer or diabetes, were excluded. Those who
had HIV or renal disease were also excluded. LTBI and
normal control groups were defined based on TSTs and
QFT-IT tests: 26 of the 51 TB contacts showed positive
IFN-g responses by the QFT-IT tests and were considered
most likely to have LTBI compared with the 25 TB contacts
with negative IFN-g responses. The control group consisted
of 55 of the 133 normal healthy individuals with negative
IFN-g responses by the QFT-IT tests and with <10 mm of
TST induration size. Therefore 58 TB patients, 26 TB
Figure 1 Enrolment of subjects and collection of samples. Active TB patients at diagnosis (n Z 86), TB contacts (n Z 51),
normal healthy controls (n Z 133), and NTM patients at diagnosis (n Z 42) were recruited. TB patients with cancer, diabetes,
or who had taken any immunosuppressant (n Z 28) were excluded. QFT-IT negative TB contacts (n Z 25) were excluded. Among
the 133 healthy controls recruited, only the subjects who showed negative responses in both TSTs (<10 mm) and QFT-IT tests were
included (nZ 55). TB patients were re-evaluated after 2 and 6 months of anti-TB treatment. Sera and QFT-IT plasma samples were
collected from each group.
348 Y.-G. Hur et al.contacts and 55 normal healthy controls were included in
the analysis of this study (Table 1).
Anti-TB treatment for TB patients included rifampicin,
isoniazid, ethambutol, and pyrazinamide for at least 6
months based on the Korean Guidelines for Tuberculosis
2011.13 The standard treatment regimen includes the 4
drugs for the first two months after which the continuation
phase consists of four months of rifampicin, ethambutol
and isoniazid. In the case of patients with drug resistance,
known patterns of resistance, drug susceptibility testing
data and drug intolerance were considered for the anti-
TB therapy. TB patients were re-evaluated with blood
collection after 2 months of anti-TB treatment and post
treatment (6 months), and 38 of the TB patients recruited
were included in the analysis of the 2 and 6 month re-
evaluations during anti-TB treatment (Table 1). However,
much less patients were included for the analysis withTable 1 Characteristics of subjects involved in the analysis
patients except for one patient with extrapulmonary TB. Amon
and 6 months post-treatment, 31 patients were M. tb culture pos
conversion at 2 months post-treatment. Eight of the 58 patients (1
Based on the results of chest radiograph, TST and QFT-IT test, 26
group of LTBI and control.
TB (n Z 58)
Mean age (range) 32 (22e76)
Male, na (%) 32 (55.2)
Body mass index, median (IQRb) 20.3 (18.9e21.9)
Presence of BCG scar, n (%) 33 (56.9)
Prior TB treatment, n (%) 5 (8.6)
Drug resistant TB, n (%) 8 (16.3)
Extrapulmonary TB, n (%) 1 (1.7)
Pulmonary TB diagnosis, n (%)
M. tb. culture, positive 50 (86.2)
M. tb. culture, negative 7 (12.1)
Extent of lesion in pulmonary TB, n (%)
One-third of lung field 44 (75.9)
Two-thirds of lung field 9 (15.5)
More than two-thirds of lung field 5 (8.6)
Culture conversion at 2 months, n (%) 45/50 (90.0)
a Number.
b Interquartile range.QFT-IT plasma samples as many of the QFT-IT plasma sam-
ples were not available; 21 TB patients at pre-treatment,
14 after 2 months of treatment, and nine after 6 months
of treatment (Fig. 1). The immune responses of 21 TB pa-
tients were compared with those of 13 individuals with
LTBI and 21 controls (Fig. 1).
All patients were prospectively recruited at Severance
Hospital in Seoul, South Korea, and the study was explained
to the study participants, and informed written consent
was obtained for interviews and all tests, including TST,
clinical examination (e.g. chest X-ray), and blood sampling
for immunological testing such as QFT-IT tests. Ethical
permission for this study was granted by the Severance
Hospital Ethics Review Committee: approval number 4-
2010-0213 for active pulmonary TB patients, TB contacts,
normal healthy controls, and approval number 4-2011-0241
for NTM patients.at baseline. Pulmonary TB was diagnosed in all of the 58 TB
g the 38 TB patients who were included in follow-ups at 2
itive at baseline while 30 out of the patients showed culture
3.8%) and 3 of the 38 patients (7.9%) were AFB smear-positive.
TB contacts and 55 normal healthy controls were defined as a
TB fir follow-up
(n Z 58)
LTBI
(n Z 26)
Control
(n Z 55)
32 (22e69) 47 (22e69) 30 (22e57)
18 (47.4) 9 (34.6) 24 (43.6)
19.9 (18.7e21.9) 22.6 (21.3e24.0) 20.3 (20.3e23.7)
23 (60.5) 22 (84.6) 35 (63.6)
2 (5.3) 2 (7.7) 0 (0)
2 (6.5)
1 (2.6)
31 (81.6)
6 (15.8)
29 (76.3)
7 (18.4)
2 (5.3)
30/31 (96.8)
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TSTs were administered by intradermal injection of 0.1 mL
of tuberculin purified protein derivative (RT-23, Statens
Serum Institute, Copenhagen, Denmark) for TB patients, TB
contacts and normal healthy controls. The reaction was
read at 48 and 72 h later and the induration size of 10 mm
was considered as a cut-off point for a positive reaction.
QFT-IT tests
Serum samples were obtained from 4 mL of blood
(VACUETTE serum tube, Greiner Bio-One GmbH, Fricken-
hausen, Germany) and 3 mL of blood was collected directly
into each of three QFT-IT tubes (Nil, M. tb Ag tube; ESAT-6,
CFP-10, and TB 7.7 peptide antigens, and mitogen tube;
PHA, Cellestis, Valencia, CA, USA). The QFT-IT tubes were
incubated upright at 37 C for 24 h, and plasma was har-
vested. Plasma samples were divided into aliquots for
IFN-g ELISAs and multiplex bead arrays. The IFN-g ELISAs
were performed according to the manufacturer’s protocol
(QuantiFERON-TB Gold, Cellestis), and the data were ana-
lysed using QFT-IT Analysis Software (Cellestis).
Measurement of cytokine concentrations
Multiplex bead arrays with 17 different analytes, including
cytokines, chemokines, and a growth factor, were per-
formed using sera and QFT-IT plasma samples using BD
FACSVerse (BD Biosciences, San Jose, CA, USA). The
analytes included IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-12p70, IL-13, IL-17A, IL-22, IFN-g, TNF-a, IFN-a, sCD40L,
CXCL10 (IP-10), and vascular endothelial growth factor A
(VEGF-A). The manufacturer’s protocol (eBioscience, San
Diego, CA, USA) was followed for the multiplex bead arrays.
The concentration of each analyte was calculated using
FlowCytomix Pro software (eBioscience), and values out of
standard curve ranges were adjusted by setting minimum
and maximum values. Values of 17 analytes in QFT-IT
plasma were corrected for background levels by subtracting
negative control values (nil tubes). In order to abate false
positive responses, responders were defined as those who
showed higher values than twice the limits of detection in
standard curves: 5.5 pg/mL for IL-9, 27 pg/mL for IL-17A,
34.5 pg/mL for CXCL10, 55 pg/mL for IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12p70, IL-13, IFN-g, TNF-a, IFN-a, VEGF-A,
110 pg/mL for sCD40L, and 220 pg/mL for IL-22.
Statistical analysis
Concentration differences of the 17 analytes from sera and
QFT-IT plasma samples from active TB patients, TB contacts
with LTBI, and normal healthy controls were analysed by
KruskaleWallis tests and Dunn’s multiple comparison tests.
Mann Whitney tests were used to analyse concentration
differences of 17 analytes between active TB and NTM
diseases. Concentrations of the 17 analytes between pre-
and post-treatment in TB patients were analysed by
Wilcoxon signed rank tests. P values were adjusted using
Bonferroni correction to account for multiple comparisons.
Diagnostic values of 17 analytes in sera and QFT-IT plasmawere examined by analysis of the area under the receiver
operating characteristic (ROC) curves (AUC).
Results
Biosignature of 17 analytes in sera from active TB
and NTM patients, TB contacts with LTBI, and
normal healthy controls
Median concentrations of serum IL-22, CXCL10, and VEGF-A
were significantly higher in 58 TB patients than in 55
controls (P < 0.05) while only VEGF-A concentration
differed between active TB and LTBI groups (P < 0.01)
(Fig. 2A). Analysis of the AUC indicated that serum VEGF-
A could be a good biomarker for discriminating active TB
from LTBI (AUC Z 0.7576, P < 0.001; Supplementary
Fig. 1).
Concentrations of the 17 analytes in the sera from 38 TB
patients (Table 1), before treatment, were compared with
those from 42 NTM patients at diagnosis. TB patients had
significantly higher concentrations of Th1 and Th2 cyto-
kines, as well as IL-17, than did the NTM patients. Five
out of the 17 analytes (IL-2, IL-9, IL-13, IL-17 and TNF-a)
were detected at statistically significant higher levels in
TB patients than in NTM patients (Fig. 2B). On the other
hand, TB patients showed significantly lower concentra-
tions of sCD40L (P < 0.01) than did the NTM patients. IFN-
g, CXCL10 and VEGF-A did not differ between the two
groups (Fig. 2B).
Biosignature of 17 analytes in QFT-IT plasma from
TB patients, TB contacts with LTBI, and controls
In response to M. tb antigen stimulation, QFT-IT plasma IFN-
g, IL-2, and CXCL10 responses were significantly higher in
active TB and LTBI groups than in the control group
(P < 0.01, Fig. 3A). TB patients also presented higher levels
of IL-13 than did the control group although the differences
were not significant (P > 0.05). QFT-IT plasma VEGF-A did
not differentiate between active TB and LTBI groups unlike
serumVEGF-A, and none of the 17 analytes differed between
the two groups in response toM. tb antigens (Fig. 3A). All cy-
tokines were highly produced in response to mitogen (PHA)
without any significant difference between the groups
(P> 0.05), suggesting that there were no non-specific immu-
nosuppression effects on the cytokine responses toM. tb an-
tigens in the QFT-IT plasma samples (Fig. 3B).
Longitudinal analysis of immune responses in sera
from active TB patients during anti-TB treatment
The effect of anti-TB treatment on immune responses was
monitored 2 and 6 months after the initiation of anti-TB
treatment. In the sera from TB patients, the sCD40L
concentration significantly increased along with M. tb
clearance in culture at the 2-month evaluation
(P < 0.001, Fig. 4). Increased serum sCD40L concentrations
were present in 79% (30 out of 38) of TB patients after 2 and
6 months of treatment. One out of 38 patients at pre-
treatment and 6 months post treatment did not have
Figure 2 Comparison of serum cytokine concentrations in groups of TB, LTBI, control and NTM. A. Concentrations of 17 cy-
tokines in TB patients (nZ 58), TB contacts with LTBI (nZ 26), and controls (nZ 55). TB patients presented significantly higher IL-
22, CXCL10, and VEGF-A serum levels compared with controls. Only VEGF-A level differed between TB patients and individuals with
LTBI (P < 0.01). B. Serum cytokine concentrations in TB (n Z 38) versus NTM (nZ 42) patients. Five of the 17 analysed cytokines
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showed positive sCD40L concentrations (>110 pg/mL) after
2 months of anti-TB treatment (Supplementary Fig. 2). The
proportion of the responders who showed <7000 pg/mL of
serum sCD40L at baseline (59.5%; 22 out of 37) was reduced
to 18.4% (7 out of 38) and 18.9% (7 out of 37) after 2 and 6
months of treatment, respectively (Supplementary Fig. 2).
Meanwhile, the number of TB patients showing >7000 pg/
mL of sCD40L increased from 16 (43.2%) to 32 (86.5%)
following anti-TB treatment (Supplementary Fig. 2). Serum
VEGF-A concentrations were reduced in more than half of
TB patients (55.3%; 21 out of 38) after 6 months of treat-
ment, whereas the change in median concentrations be-
tween pre- and post-treatment was not statistically
significant (P > 0.05). Sera concentrations of the other an-
alytes, including IFN-g, did not change during anti-TB treat-
ment in 38 TB patients (Fig. 4).
Longitudinal analysis of immune responses in QFT-
IT plasma from active TB patients during anti-TB
treatment
In the QFT-IT plasma obtained from active TB patients, the
IFN-g responses were dramatically decreased in 85.7% (12
out of 14) of the TB patients after 2 months of treatment.
Eight out of the 12 patients showed confirmed M. tb in cul-
ture at diagnosis while M. tb clearance was observed along
with the reduced IFN-g responses at 2 months post treat-
ment. Additionally, all patients showed reduced IFN-g re-
sponses post-treatment (P < 0.001, Fig. 5). Eight out of
14 TB patients showed positive TNF-a responses at baseline
and the TNF-a responses decreased in all of the responders
after 2 months of treatment (P < 0.05, Fig. 5). Further-
more, 69.2% (9 out of 13) and 58.3% (7 out of 12) of the re-
sponders after 2 months of treatment showed reduced IL-2
and CXCL10 responses, respectively, though the magnitude
of the immune responses was not significant compared to
pre-treatment levels. QFT-IT plasma TNF-a and CXCL10 re-
sponses were decreased in only 33% of the TB patient post-
treatment, indicating that M. tb antigen-specific TNF-a and
CXCL10 may act as regulating cytokines during the early
phase of treatment. The percentage of responders showing
relatively low IFN-g production (<500 pg/mL) gradually
increased to 50% after 2 months of treatment and 78%
post-treatment (6 months). Meanwhile, the percentage of
the responders with high IFN-g production (>1000 pg/mL)
was significantly reduced to 11.1% from 47.6% following 6
months of treatment (Supplementary Fig. 2). A similar
pattern was found with TNF-a and IL-2 responders
throughout treatment (Supplementary Fig. 2).
Discussion
Current diagnostic tests for TB mainly depend on detection
of clinical isolates by AFB smear microscopy and culture,such as IL-2, TNF-a, IL-13, IL-9 and IL-17 were detected at higher
concentration was significantly higher in NTM patients than in TB
horizontal bars. (*P < 0.05, **P < 0.01).both of which have limited accuracy and speed.2,3
Recently, the IGRA was developed to quickly determine
M. tb infection with higher specificity compared with TST,
whereas the IFN-g levels alone are not sufficient to differ-
entiate between LTBI and active TB disease.8,9 Based on
the need for biomarkers to improve diagnosis of active
TB, LTBI, and NTM disease and for monitoring therapeutic
effects, we examined the biosignatures of 17 analytes in
serum and M. tb antigen-stimulated plasma samples (QFT-
IT plasma) that were obtained from active TB and NTM pa-
tients, TB contacts with LTBI, and normal healthy controls.
Our results suggest that serum VEGF-A concentrations may
help to differentiate between active TB and LTBI in addi-
tion to the diagnosis of TB by culture-confirmed M. tb. Mea-
surement of serum IL-2, IL-9, IL-13, IL-17, TNF-a and
sCD40L concentrations may also improve diagnosis discrim-
inating between TB and NTM. Increased concentrations of
serum sCD40L and decreased M. tb-specific IFN-g, TNF-a,
and IL-2 responses were associated with M. tb conversion
in culture after 2 months of treatment, indicating the use-
fulness of the cytokines as indicators for monitoring thera-
peutic effects in active TB patients.
Increased VEGF levels have been reported in granulo-
matous diseases, such as pulmonary TB,14 Crohn’s dis-
ease,15 and sarcoidosis.16 Higher levels of serum VEGF
were found in patients with active TB11 and mycobacterium
avium complex (MAC) infection17 compared with normal
controls, and circulating VEGF concentrations correlated
with disease severity in active TB.18 In this study, the me-
dian concentration of serum VEGF-A was significantly higher
in TB patients than in the LTBI and control groups. Higher
levels of VEGF have been also reported in saliva or plasma
of TB patients compared with healthy controls.19,20 Howev-
er, in response to M. tb antigen stimulation, we did not
observe any differences in VEGF responses between active
TB and LTBI although VEGF responses in QFT-IT supernatant
differed between the groups in other studies.9,21 Levels of
IFN-g, IL-2, and CXCL10 in QFT-IT supernatant were signifi-
cantly higher in TB patients than in normal controls
whereas none of the 3 analytes clearly differentiated be-
tween TB and LTBI as previously reported.9,22,23 These
data indicate that assessment of a combination of IL-2
and CXCL10 may enhance the sensitivity of IGRA that mea-
sures only IFN-g levels for diagnosis of M. tb infection. In
addition, serum VEGF-A concentrations may serve as a
biomarker to discriminate TB from LTBI. The relatively
low specificity of serum VEGF-A concentrations may be
improved by the combined measurement of IFN-g, IL-2
and CXCL10 in response to M. tb antigens. Molecular tests
have high specificity and sensitivity for rapid diagnosis
and differentiation between pulmonary TB and NTM dis-
eases,5,6 but our data also provide a panel of serum cyto-
kines (IL-2, IL-9, IL-13, IL-17, TNF-a and sCD40L) for
differential diagnosis of active TB and NTM (P < 0.01).
This panel may aid in early diagnosis prior to identification
of clinical isolates by culture.levels in TB patients than in NTM patients. In contrast, sCD40L
patients (P < 0.01). Median concentrations are indicated with
Figure 3 Cytokine responses to M. tb ESAT-6, CFP, and TB 7.7 in QFT-IT plasma of TB (n Z 21), LTBI (n Z 13), and control
(nZ 21) groups. A. In response to M. tb-specific antigens, IFN-g, IL-2 and CXCL10 responses were significantly higher in active TB
and LTBI than in controls. None of the analytes differed between TB and LTBI groups. B. In response to PHA, all cytokines were
greatly expressed in all three groups. Median responses are indicated with horizontal bars. (**P < 0.01).
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Figure 4 Concentration changes of serum cytokines in TB patients during anti-TB treatment. Concentrations of serum cyto-
kines were measured in 38 TB patients at pre-treatment, after 2 months of treatment, and post-treatment (6 months). Most of the
cytokine concentrations were not altered during anti-TB treatment. However, 29 out of the 38 TB patients showed increased serum
sCD40L concentrations after 2 months of treatment (P < 0.001).
Biosignatures associated with TB, LTBI, and NTM diseases 353CD40L (CD154) is a co-stimulatory molecule that plays a
role in enhancing cell-mediated immunity to intracellular
pathogens by inducing IL-12, which subsequently generates
Th1-type cytokines through interactions with CD40 on
macrophages or dendritic cells.24 Defective CD40L expres-
sion in PBMCs from TB patients contributes to decreased
IFN-g production by PBMCs.25 Significantly higher levels
of plasma sCD40L is present in plasma from TB patients
in the fifth week of anti-TB treatment compared to pre-
treatment,7 which is consistent with our findings. Howev-
er, sCD40L responses did not change significantly in
response to M. tb antigens. It has been suggested that
the IGRA is not appropriate as a monitoring tool for anti-
TB treatment due to the substantial proportion of patients
with positive QFT-IT (46%) and T-SPOT.TB (79%) results af-
ter TB treatment.26 There was no difference in IP-10 levels
of QFT-IT plasma between pre- and post-treatment
whereas significant changes in IP-10 release were observed
in response to RD1 selected peptides (ESAT-6 and CFP-
10).27 Our study also showed no significant change in IP-10 levels of QFT-IT plasma between baseline and post-
treatment. Meanwhile, both the magnitude of IFN-g re-
sponses and the proportion of the responders showing
high IFN-g production (>1000 pg/mL) were significantly
reduced post-treatment (P < 0.001). Rapid decreases in
TNF-a and IL-2 responses and the percentage of responders
correlated with M. tb sputum conversion in culture after 2
months of treatment. These results suggest that screening
levels of serum sCD40L together with M. tb antigen-
specific IFN-g, TNF-a, and IL-2 responses may help eval-
uate drug efficacy, particularly the early therapeutic ef-
fect, in TB patients. However, our findings of M. tb
antigen-specific IFN-g, TNF-a, and IL-2 responses should
be further tested considering the limited samples sizes at
2 months (n Z 14) and 6 months (n Z 9) follow-up time
points.
Any association was not observed between the patients
who had consistently higher levels of analytes in their sera
versus plasma versus culture positivity. There was no
correlation between cytokine signatures and the M. tb
Figure 5 Changes in cytokine responses to M. tb antigens in TB patients during anti-TB treatment. QFT-IT plasma cytokine
responses were followed up in 21 TB patients at pre-treatment, 14 patients after 2 months of treatment, and nine patients after
6 months of treatment. The IFN-g and IL-2 responses were gradually reduced during treatment, whereas TNF-a responses were
rapidly reduced after 2 months of treatment (P < 0.05) compared to other cytokine responses. Decreased plasma IFN-g responses
were found in all patients after 6 months of treatment (P < 0.001).
354 Y.-G. Hur et al.family (Beijing versus Non-Beijing) identified in the TB
patients (P > 0.05, data not shown). Additionally, there was
no evidence of significant differences between cytokine sig-
natures and the NTM species identified (P > 0.05, data not
shown). However, these results will likely hold true in
future studies with larger sample sizes.
In conclusion, serum VEGF-A is the most informative
marker for distinguishing active TB from LTBI, and a panel
of serum IL-2, IL-9, IL-13, IL-17, TNF-a and sCD40L levels
may contribute to more accurate and rapid differential
diagnosis between active TB and NTM disease. Serum
sCD40L levels and M. tb antigen-specific IFN-g, TNF-a,
and IL-2 responses could be a biomarker associated with
treatment responses when combined with M. tb clearance
in sputa cultures. Measurement of multiple analytes in
serum or QFT-IT plasma could speed up diagnosis and may
be utilised as a surrogate marker. In addition, it would
greatly benefit the development of diagnostics to differen-
tiate between active TB versus LTBI or active TB versus NTM
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